Skip to main content
VTGN
NASDAQ Life Sciences

Vistagen's Fasedienol Fails Phase 3 Primary Endpoint for Social Anxiety

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.26
Mkt Cap
$31.185M
52W Low
$0.43
52W High
$5.14
52W Position info
40% below low
Off High info
95% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

VTGN is trading near its 52-week low of $0.43 (40% below the low) on elevated volume (2.0× avg).

Summary

Vistagen Therapeutics announced its fasedienol nasal spray failed to meet the primary endpoint in a Phase 3 trial for acute social anxiety disorder, with no treatment difference observed for secondary endpoints. This is a significant setback for a key pipeline asset, especially for a company that recently disclosed substantial doubt about its ability to continue as a going concern. While the company noted favorable safety and plans to discuss a new registrational pathway with the FDA, including a potential future Phase 3 trial, the immediate failure of a pivotal study's primary endpoint is a major blow to its drug development efforts and valuation.

At the time of this announcement, VTGN was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.2M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

VTGN - Latest Insights

VTGN
Nov 13, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1805
Real-time Price: $0.1829 info
Change: +$0.0024 (+1%) info
Market Cap: $8.618M info
VTGN
Nov 13, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1805
Real-time Price: $0.1829 info
Change: +$0.0024 (+1%) info
Market Cap: $8.618M info
VTGN
Nov 09, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.172
Real-time Price: $0.1829 info
Change: +$0.0109 (+6%) info
Market Cap: $8.618M info
VTGN
Oct 30, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1714
Real-time Price: $0.1829 info
Change: +$0.0115 (+7%) info
Market Cap: $8.618M info
VTGN
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2461
Real-time Price: $0.1829 info
Change: -$0.0632 (-26%) info
Market Cap: $8.618M info